Promising Chinese Alzheimer’s drug to see $3bn investment over next 10 years

Richard Tadd Industry News

The Chinese pharmaceutical market sees another significant victory in recent weeks as it is announced that China has conditionally approved the first new Alzheimer’s drug to hit the global market in 17 years, and it will be distributed worldwide for long-term testing. The seaweed-derived drug GV-971, more colloquially known as Oligomannate, appears to improve cognition in patients with mild to …

Tackling the 2019-nCoV coronavirus – what the experts are doing

Richard Tadd Blog

The emergence of a new, potentially dangerous coronavirus in the city of Wuhan in China’s Hubei province has sparked a flurry of articles in the international media and widespread discussion on social media, much of it poorly informed or coloured by politics. With epidemiologists from multiple nations working together to tackle the outbreak, cooperation and the clear exchange of information …

Real-world evidence regulations are on the way

Richard Tadd Blog

The last decade has seen increasing emphasis worldwide on the importance of well-regulated, real-world data collection and analysis as a follow-up to clinical trials for new medicines and medical devices. China is now taking steps to make regulatory changes of its own in this area. On 7 January 2020, the National Medical Products Association (NMPA) released a paper entitled Guiding …

Concerns over US clinical trials as it is revealed only 41% of results are reported in accordance with new laws

Richard Tadd Industry News

In January 2017, the US passed new regulations to ensure that all clinical trials would have their results reported within one year of primary completion – with hefty fines of up to US$10,000 a day for those who failed to comply with the new rules. Despite this, a recent study published by The Lancet found that almost six in 10 …

‘Bureaucracy’ is one of the greatest threats to clinical research

Richard Tadd Industry News

In 2013, Christina Reith, fellow of The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, lead authored a paper that addressed in no uncertain terms what effect red tape was having on clinical trials in Europe. Her conclusions were damning – that for academics engaged in carrying out randomised control trials, the most pressing of issues were those …